Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23260Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gordon, J. | en |
| dc.contributor.author | Challa, A. | en |
| dc.contributor.author | Levens, J. M. | en |
| dc.contributor.author | Gregory, C. D. | en |
| dc.contributor.author | Williams, J. M. | en |
| dc.contributor.author | Armitage, R. J. | en |
| dc.contributor.author | Cook, J. P. | en |
| dc.contributor.author | Roberts, L. M. | en |
| dc.contributor.author | Lord, J. M. | en |
| dc.date.accessioned | 2015-11-24T19:31:24Z | - |
| dc.date.available | 2015-11-24T19:31:24Z | - |
| dc.identifier.issn | 1350-9047 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23260 | - |
| dc.rights | Default Licence | - |
| dc.subject | Antibodies, Monoclonal/pharmacology | en |
| dc.subject | B-Lymphocytes/drug effects/*metabolism | en |
| dc.subject | Burkitt Lymphoma/drug therapy/*metabolism/pathology | en |
| dc.subject | CD40 Ligand/*metabolism/pharmacology | en |
| dc.subject | Cell Death | en |
| dc.subject | Cell Line | en |
| dc.subject | DNA/metabolism | en |
| dc.subject | Escherichia coli/metabolism | en |
| dc.subject | Humans | en |
| dc.subject | Ionomycin/pharmacology | en |
| dc.subject | Protein Subunits | en |
| dc.subject | Proto-Oncogene Proteins c-bcl-2/genetics/*metabolism | en |
| dc.subject | Receptors, Cell Surface/*metabolism | en |
| dc.subject | Shiga Toxin 1/metabolism/*pharmacology/therapeutic use | en |
| dc.subject | Signal Transduction | en |
| dc.subject | Trihexosylceramides/*metabolism | en |
| dc.subject | bcl-X Protein | en |
| dc.title | CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxin | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1038/sj.cdd.4400710 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/11042673 | - |
| heal.identifier.secondary | http://www.nature.com/cdd/journal/v7/n9/pdf/4400710a.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2000 | - |
| heal.abstract | Owing to its lineage and differentiation stage-restricted expression, CD77 has been mooted as a therapeutic target in Burkitt lymphoma (BL). The recognition that the globotriaosyl moiety of this neutral glycosphingolipid is a receptor for Escherichia coli-derived Verotoxin-1 (Shiga-Like Toxin-1) offers a potential delivery system for the attack. Here we show that CD77-expressing Group I BL cells which are normally susceptible to activation-induced death on binding Verotoxin-1 B chain are protected in the presence of CD40 ligand. Ectopic expression of either bcl-2 or bcl-xL also afforded resistance to the actions of the B chain. In total contrast, neither of the survival genes nor a CD40 signal - even when acting in concert - protected against killing mediated by the holotoxin. These findings indicate that while therapeutic modalities for CD77-expressing B cell tumors (which include follicular lymphoma) based on the use of Verotoxin-1 B chain might be compromised by the activation of endogenous or exogenous survival pathways, those exploiting the holotoxin should be left unscathed. | en |
| heal.journalName | Cell Death Differ | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Gordon-2000-CD40 ligand, Bcl-2.pdf | 326.64 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
